Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5954339 | 0.85 | KDM4E (0.38) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL3394855 | 0.82 | KDM4E (0.30) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL2746651 | 0.79 | MAP3K5 (0.37) | — | |
| SCHEMBL252254 | 0.79 | KDR (0.43) | — | |
| SCHEMBL2746971 | 0.78 | ALDH1A1 (0.34) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL251983 | 0.69 | KDR (0.43) | — | |
| SCHEMBL3405758 | 0.68 | RAB9A (0.35) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5954348 | 0.68 | PDGFRB (0.31) | — | |
| SCHEMBL5955024 | 0.67 | KDR (0.44) | — | |
| SCHEMBL253680 | 0.67 | CSNK1D (0.44) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063054-A1 | cMET INHIBITORS | CEPT1, LCAT, GNMT | KDM4E 664/4885NPC1 313/4885ALDH1A1 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.